anoth strong quarter alexion beat consensu total sale driven
strong perform complement franchis well increas volum strensiq
compani also beat non-gaap ep manag rais full
year sale guidanc reflect continu optim growth soliri ultomiri
convers continu track well patient convert us
germani japan final compani put place share repurchas
author earmark share stabil futur year primari focu
capit deploy remain build pipelin
alexion continu solid fundament believ oper
perform date underli strong competit posit alexion expect
complement franchis continu deliv growth next year driven
emerg neuro franchis sever way competit overhang issu
resolv favor come year strong execut record share still trade
well view fair valu highlight top idea current level
sever avenu valu creation pursu
conserv bd strategi favor smaller tuck-in deal compani made
signific progress last year develop potenti area expans
complement franchis creat diversif therapeut categori though
gener earlier stage recent explor way alexion could eventu favor
resolv trade rang mire last year continu think
may hidden sourc option within alxn pipelin includ ultomiri
al compani program expect interim data early-
could rapidli establish competit posit asset within fcrn
landscap low-volum weekli better sc inject
model updat incorpor actual model adjust revenue/
expens project increas tp vs prior non-gaap ep
vs prior risk thesi includ clinic regulatori commerci
headwind competitor updat
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
alexion biotechnolog compani focus research develop
commerci therapeut rare diseas alexion drug soliri
use treat patient complement mediat disord
product includ strensiq kanuma
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
abl convert major soliri patient prior
launch biosimilar continu strength gmg launch posit
nmo data increas pipelin valu
unabl convert major soliri patient prior
launch biosimilar eu/row weak gmg trend failur
nmo decreas pipelin valu
 close
million except ep actualcon qoq yoy incom tax incom incom dil guidanc guidanc guidanc mcomplement mmetabol mr total total per charl martineau univers toronto octob
compani mention price
martin auster certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view
express report
